Loading...
•
Jun 30, 2020
Viridian Therapeutics Q2 2020 Earnings Report
miRagen Therapeutics reported financial results for Q2 2020 and provided business updates.
Key Takeaways
miRagen Therapeutics reported a net loss of $6.4 million, or $0.12 per share, for the second quarter of 2020. Cash and cash equivalents were $30.6 million as of June 30, 2020, and the company believes its cash will fund operations into Q3 2021.
Progress on next generation microRNA-29 mimic for use in pulmonary fibrosis (MRG-229) includes new preclinical data and additional NIH grant funding.
Exploratory preclinical safety and pharmacokinetic data for MRG-229 expected before year end.
Plan to receive guidance from the FDA on proposed regulatory pathway for cobomarsen in ATLL before year end.
A majority of patients in the Phase 2 SOLAR trial of cobomarsen in CTCL have continued to receive uninterrupted treatment and are being evaluated for clinical response.
Forward Guidance
miRagen believes that its current cash and cash equivalents will be sufficient to fund the Company’s operations into the third quarter of 2021.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...